Campath halts MS disability progression in Phase II trial
This article was originally published in Scrip
Executive Summary
Genzyme and Bayer HealthCarehave announced positive final results from a head-to-head Phase II trial of their leukaemia drug Campath (alemtuzumab) versus Rebif (high-dose interferon beta-1a) in patients with early relapsing-remitting multiple sclerosis. The data showed that Campath improved patients' mean disability EDSS score, while the scores of those taking Rebif – a standard MS treatment, deteriorated. The findings were published in the October 23rd issue of the New England Journal of Medicine.